Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus chemotherapy in resectable NSCLC
NCT05170581Phase 2Unknown
- Sponsor
- Second Affiliated Hospital of Shandong First Medical University
- Start
- Dec 2021
- Primary completion
- Nov 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab in non-small cell lung cancer (NSCLC), sponsored by Second Affiliated Hospital of Shandong First Medical University. Primary endpoints: Major Pathological Remission at 3 years and Event-free Survival at 3 years. Status: unknown.
02
Drugs
sintilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05170581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05170581.